Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068665 · ClinicalTrials.gov registry record · Phase 3
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT01068665 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 460 participants.
The verdict
NCT01068665, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing treatment with metformin and/or dipeptyl peptidase 4 (DPP-4) inhibitors, in patients with type 2 diabetes being treated with oral anti-diabetic drugs (OADs) qualifying for intensified treatment.
Interventions
- DRUG insulin glargine
- DRUG insulin degludec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01068665
The ClinicalTrials.gov registry entry for NCT01068665 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT01068665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01068665 about?
NCT01068665 is a clinical study titled "Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes". This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing treatment with metformin and/or dipeptyl peptidase 4 (DPP-4) inhibitors, in pat...
What is the current status of trial NCT01068665?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2010-03. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01068665?
The interventions under investigation include: insulin glargine (DRUG), insulin degludec (DRUG).
Who is sponsoring clinical trial NCT01068665?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.